Sukhkarn Bains, MD
Internal Medicine · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 10 years
- New York University School of Medicine, 2016
Offices
2 locations · Southern California Permanente Medical Group · Geoffrey Trenkle DO A Professional Medical Corporation
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bains’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A151756 · Current
Licensed to practise in California · since 2017 · expires 2027-04-30 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Allergy and Immunology - Allergy and Immunology
- American Board of Internal Medicine - Internal Medicine
Original Medicare doctor bills
$5,061
Medicare paid this office $5,061 for 76 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Test for allergy using allergenic extract | 13 | $1,692 | $3 |
| Professional service for multiple injections of allergen | 48 | $1,608 | $11 |
| Return visit (30+ min) | 13 | $1,487 | $99 |
Who their Medicare patients are
76 Original Medicare patients in 2024. Average age 69 · Under 65 24% · Women 50% · Also on Medicaid 43% · Health risk score 1.17. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 72% · Diabetes 34% · Depression 25% · COPD 24% · Coronary heart disease 22% · Chronic kidney disease 22% · Atrial fibrillation 21% · Cancer 18% · Heart failure 16%.
The office billed $15,177, Medicare allowed $6,454 and paid $5,061; for 694 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$75 in 2024
Medicaid paid $75 for 222 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 222 | $75 |
| 2024 | 222 | 1 | 34 | $75 |
| 2023 | 27 | 2 | 15 | $0 |
| 2022 | 20 | 1 | 19 | $0 |
See the largest Medicaid services in earlier years
2023
| TOBACCO NON-USER | 12 | $0 |
| Service(s) provided in the office during regularly scheduled evening, weekend, or holiday office hours, in addition to basic service | 15 | $0 |
2022
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 20 | $0 |
Drugs they prescribed that Part D paid
$27,689
Pharmacies billed $27,689 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
279 generic and 92 brand-name prescriptions · $27,689 in drug cost · 145 antibiotic prescriptions to 138 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Spiriva Respimat | 12 | $5,930 | $494 |
| Epinephrine | 13 | $1,728 | $133 |
| Albuterol Sulfate Hfa | 27 | $457 | $17 |
| Nitrofurantoin Mono-Macro | 47 | $455 | $10 |
| Azelastine | 17 | $355 | $21 |
See all 11 drugs
| Spiriva Respimat | 12 | $5,930 | $494 |
| Epinephrine | 13 | $1,728 | $133 |
| Albuterol Sulfate Hfa | 27 | $457 | $17 |
| Nitrofurantoin Mono-Macro | 47 | $455 | $10 |
| Azelastine | 17 | $355 | $21 |
| Montelukast | 19 | $206 | $11 |
| Amoxicillin-Clavulanate Potass | 14 | $192 | $14 |
| Prednisone | 17 | $155 | $9 |
| Cefadroxil | 15 | $149 | $10 |
| Azithromycin | 21 | $140 | $7 |
| Paxlovid | 26 | $0 | $0 |
Year by year
| 2024 | 382 | 298 | None | 24% | $27,689 |
| 2023 | 562 | 371 | None | 18% | $49,186 |
| 2022 | 1,212 | 356 | 7% (81) | 13% | $55,529 |
| 2021 | 437 | 158 | 6% (24) | None | $30,300 |
| 2020 | 212 | 61 | None | None | $22,214 |
| 2019 | 85 | 27 | None | None | $9,256 |
| 2018 | 19 | None | None | 0% | $319 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Spiriva Respimat | 15 | $5,426 | $362 |
| Wixela Inhub | 17 | $4,545 | $267 |
| Albuterol Sulfate Hfa | 50 | $871 | $17 |
| Paxlovid (Eua) | 45 | $765 | $17 |
| Azelastine | 37 | $743 | $20 |
| Fluticasone Propionate | 17 | $260 | $15 |
| Atorvastatin | 15 | $223 | $15 |
| Prednisone | 29 | $216 | $7 |
| Amoxicillin-Clavulanate Potass | 14 | $185 | $13 |
| Cephalexin | 16 | $155 | $10 |
| Azithromycin | 21 | $151 | $7 |
| Montelukast | 13 | $131 | $10 |
2022: 33 drugs
| Wixela Inhub | 13 | $2,282 | $176 |
| Alvesco | 15 | $1,273 | $85 |
| Atorvastatin | 76 | $1,060 | $14 |
| Diclofenac | 28 | $1,012 | $36 |
| Albuterol Sulfate Hfa | 52 | $876 | $17 |
| Hydrocodone-Acetaminophen | 47 | $852 | $18 |
| Gabapentin | 22 | $622 | $28 |
| Levothyroxine | 28 | $598 | $21 |
| Lisinopril | 37 | $472 | $13 |
| Amlodipine Besylate | 39 | $445 | $11 |
| Losartan | 33 | $388 | $12 |
| Fluticasone Propionate | 24 | $381 | $16 |
| Metoprolol | 14 | $358 | $26 |
| Duloxetine | 14 | $303 | $22 |
| Furosemide | 25 | $262 | $10 |
| Atenolol | 18 | $228 | $13 |
| Tamsulosin | 11 | $222 | $20 |
| Trazodone | 13 | $219 | $17 |
| Sumatriptan | 15 | $215 | $14 |
| Buspirone | 15 | $197 | $13 |
| Alendronate | 13 | $197 | $15 |
| Simvastatin | 16 | $191 | $12 |
| Carvedilol | 17 | $182 | $11 |
| Ibuprofen | 14 | $162 | $12 |
| Metformin Hcl Er | 16 | $161 | $10 |
| Metoprolol | 17 | $158 | $9 |
| Oxycodone | 15 | $154 | $10 |
| Fluoxetine | 11 | $149 | $14 |
| Lisinopril-Hydrochlorothiazide | 13 | $149 | $11 |
| Famotidine | 12 | $114 | $10 |
| Hydroxyzine | 13 | $102 | $8 |
| Ciprofloxacin | 12 | $100 | $8 |
| Prednisone | 11 | $74 | $7 |
2021: 8 drugs
| Jardiance | 12 | $6,424 | $535 |
| Diclofenac | 23 | $683 | $30 |
| Hydrocodone-Acetaminophen | 19 | $399 | $21 |
| Atorvastatin | 20 | $285 | $14 |
| Losartan | 20 | $251 | $13 |
| Albuterol Sulfate Hfa | 12 | $242 | $20 |
| Fluticasone Propionate | 13 | $206 | $16 |
| Lovastatin | 16 | $110 | $7 |
2020: 3 drugs
| Atorvastatin | 14 | $295 | $21 |
| Losartan | 16 | $102 | $6 |
| Metformin | 12 | $72 | $6 |
Money from drug and device companies
$662 in 2025
| 2025 | 7 | 11 | None | $662 |
| 2024 | 2 | 2 | None | $141 |
| 2023 | 1 | 1 | None | $152 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Nucala | $180 | 4 payments
|
| Stryker | Scopis Ent | $153 | 1 payment
|
| Medtronic | Ligasure | $148 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $81 | 1 payment
|
| Novartis Pharmaceuticals | Xolair | $52 | 2 payments
|
| Genzyme | Dupixent | $26 | 1 payment
|
See all 11 published payments
| Novartis Pharmaceuticals | Meals · 2025-11-21 | Rhapsido | $26 |
| Novartis Pharmaceuticals | Meals · 2025-11-14 | Xolair | $26 |
| Genzyme | Meals · 2025-10-24 | Dupixent | $26 |
| GlaxoSmithKline | Meals · 2025-09-05 | Nucala | $22 |
| Stryker | Meals · 2025-08-28 | Scopis Ent | $153 |
| ARS Pharmaceuticals Operations | Meals · 2025-07-18 | Neffy | $21 |
| Regeneron Healthcare Solutions | Education · 2025-03-13 | Dupixent | $81 |
| Medtronic | Meals · 2025-02-28 | Ligasure | $148 |
| GlaxoSmithKline | Meals · 2025-02-19 | Nucala | $121 |
| GlaxoSmithKline | Meals · 2025-02-14 | Nucala | $20 |
| GlaxoSmithKline | Meals · 2025-01-31 | Nucala | $17 |
See earlier years (2024, 2023)
2024: $141
| Regeneron Healthcare Solutions | Dupixent | $120 | 1 payment
|
| GlaxoSmithKline | Nucala | $21 | 1 payment
|
2023: $152
| Grifols USA | Xembify | $152 | 1 payment
|
Professional record
- NPI
- 1598128225
- Licence
- CA A151756California A151756: Current · expires 2027-04-30
- Trained
- New York University School of Medicine, 2016 · 10 years ago
- Group
- Southern California Permanente Medical Group · Geoffrey Trenkle DO A Professional Medical Corporation
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 2155 Iron Point Rd, Folsom, CA, 95630
- NPI first listed
- 2016-03-31
- NPI last updated
- 2022-07-25
- NPI record certified
- 2021-06-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 925 Seneca St, Seattle, WA, 98101
This office lists an electronic records connection.